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In this study, novel indolotacrine analogues have been designed, synthesized and evaluated as 
potential drugs for the treatment of Alzheimer’s disease. Based on a multi-target-directed ligand 
approach, novel compounds have been designed to act simultaneously as cholinesterase and 
monoamine oxidase (MAO) inhibitors. Prepared compounds were also evaluated for their 
antioxidant, cytotoxic, hepatotoxic and permeability (Blood-Brain Barrier penetration) properties. 
Indolotacrine 9b (9-methoxy-2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-amine) showed the 
most promising results in the in vitro assessment being a potent inhibitor of acetylcholinesterase (IC50 
= 1.5 µM), butyrylcholinesterase (IC50 = 2.4 µM) and monoamine oxidase A (IC50 = 0.49 µM) and a 
weak inhibitor of monoamine oxidase B (IC50 = 53.9 µM). Although its cytotoxic (IC50 = 5.5 ± 0.4 µM) 
and hepatotoxic (IC50 = 1.22 ± 0.11 µM) profile is not as good as the standard 7-methoxytacrine (IC50 
= 63 ± 4 µM and IC50 = 11.50 ± 0.77 µM respectively), the overall improvement in the inhibitory 
activities and potential to cross blood-brain barrier make indolotacrine 9b a promising lead 
compound for further development and investigation. 
 
  
 Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by progressive 
and irreversible cognitive impairment and memory loss.[1] Despite enormous efforts the aetiology of 
AD has not yet been elucidated and the disease remains incurable.[2] According to current 
knowledge, beta-amyloid (Aβ) aggregates,[3] τ-protein phosphorylation,[4] oxidative stress[5] and 
deficits of acetylcholine (ACh)[6] are considered to play significant roles in AD pathophysiology. 
The cholinergic hypothesis asserts that the decreased level of ACh in the brain leads to cognitive and 
memory deficits and that sustaining or recovering the cholinergic function should therefore result in 
amelioration of the symptoms.[7–9] Accordingly, current AD therapy is mainly based on ACh esterase 
inhibitors (AChEIs), which are able to increase ACh levels in cholinergic synapses. To date, the 
number of approved drugs is limited to three AChEIs (rivastigmine, donepezil and galantamine) and a 
NMDA antagonist (memantine). However, these drugs cannot prevent or cure the disease but afford 
only symptomatic treatment.[9,10] 
The ‘‘one-target, one-compound’’ paradigm has been highly successful in the past for many common 
diseases because their underlying molecular mechanisms were understood, allowing biologists to 
define the key target for a particular disease. Once the target was identified, medicinal chemists 
strategically designed a molecule to interact selectively with such a target, with a potential drug as 
the outcome. However, it is apparent that this target-based approach does not always guarantee 
success. Drugs directed to a single target might not always modify complex multifactorial diseases 
such as AD, even if they act in the way they are expected to proceed.[11] It is now widely accepted 
that a more effective therapy would result from the use of multipotent compounds able to intervene 
simultaneously in the different pathological events underlying the aetiology of AD.[12,13] 
Monoamine oxidase (MAO; EC 1.4.3.4) is another important target that was considered for the 
treatment of AD because some symptoms of AD are due to alterations in the dopaminergic, 
serotoninergic and other monoaminergic neurotransmitter systems.[14,15] Moreover, MAO catalysed 
oxidative deamination gives arise to production of hydrogen peroxide and, consequently, reactive 
oxygen species that have also been implicated in the progress of AD.[16] MAO inhibitors (MAOI) 
should increase monoaminergic neurotransmission and reduce reactive oxygen species formation, 
both effects potentially valuable for the treatment of AD.[13,15] Thus, in this context, multipotent 
molecules able to simultaneously bind both ChEs and MAOs have been investigated.[17–20] 
The aim of this preliminary communication was to develop novel multi-target-directed ligands 
(MTDLs) acting primarily as MAO and cholinesterase inhibitors. For this purpose we chose structural 
motifs contained in previously described MAO and/or ChEIs and incorporated them into the scaffold 
of the novel compounds. Two distinct series of molecules have been designed. The first series 
containing 2-aminoindole-3-carbonitrile structural scaffold (further referred as “indole” series; 
compounds 4a-c and 8c) employs an indole ring, that is a structural core in several MAOIs or dual-
acting compounds targeting both MAO and ChEs, such MBA236 (Figure 1),[21,22] and the β-
aminonitrile motif found in some previously identified MAOI.[23] Compounds 4b,c also contain the 
propargylamine moiety, which is an essential part of many neuroprotective, irreversible MAOIs 
(Figure 1).[24] Originally, only compounds 4a,b had been designed, however, during the synthesis of 
4b a side-product 4c was isolated. Because of the low yield obtained, 4c was tested only for its 
inhibitory activity against MAO. Compound 8c was synthesized later on to explore, whether the N-
allyl or N-propargyl substitution on the amino group in position two is important for MAO inhibition 
 and also to validate the importance of the phenolic group for the antioxidant activity of other 
compounds in the series (discussed later in the text). 
 
Figure 1: Design of indole series. 
 
The second series was then designed employing the 2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-
amine structural scaffold (described hereafter as the “indolotacrine” series; compounds 9a,b and 13) 
to improve the unsatisfactory anti-ChE activity of the indole series. For this purpose the 2-
aminoindole-3-carbonitrile scaffold of the indole series was fused with the structure of potent ChEI 
tacrine or 7-methoxytacrine (7-MEOTA). Moreover, the resulting indolotacrines also resemble β-
carboline alkaloids (e.g. harmine), which are known MAOI (Figure 2).[25,26] Since compound 4c with N-
propargyl substitution in position 1 was found to be the most potent MAOI within the indole series, it 
was decided to preserve this potentially favourable motif when designing compound 13 with benzyl 
substitution analogous to former N-propargyl moiety. 
 
 Figure 2: Design of indolotacrine series. 
 
5-Hydroxy-1H-indole-3-carbonitrile derivatives 4a-c were prepared in three steps (Scheme 1). At first 
malononitrile (1) was treated with ethanol in diethyl ether saturated with HCl (g) to obtain 3-amino-
3-ethoxyacrylonitrile (2). In next step acrylonitrile 2 was treated with the corresponding alkylamine 
to give N-alkylated 3,3-diaminoacrylonitriles 3. Lastly, diaminoacrylonitriles 3 were treated with p-
benzoquinone to give 2-(alkylamino)-5-hydroxy-1H-indole-3-carbonitriles 4a,b.[27] Moreover, a by-
product, whose structure was assigned as the alkylated in position 1  (4c), was also isolated from the 
reaction of 3-amino-3-(prop-2-yn-1-ylamino)acrylonitrile (3b). 
 
 
Scheme 1: Synthesis of indole series (4a – 4c). Reagents and conditions: a) HCl, EtOH, Et2O, 0˚C – rt, 
4h, 18%; b) alkylamine, EtOH, rt, overnight, 61-77%; c) p-benzoquinone, EtOH, rt, 1h, 10-22%. 
 
Indole 8c and indolotacrines 9a,b were prepared in two to four steps using a similar synthetic 
approach (Scheme 2). The synthesis of compound 9b started from commercial 2-iodo-4-methoxy-1-
nitrobenzene (5) which was reduced using Fe powder and ammonium chloride to the corresponding 
aniline derivative 6b. Intermediates 6a and 6c were obtained as a commercial chemicals. Further, the 
synthesis proceeded identically for three compounds. Corresponding 2-iodoaniline derivatives 6a – 
6c were treated with trifluoroacetic anhydride to give the trifluoracetamides 7a - 7c, which were 
then used for the copper iodide catalysed cyclization with malononitrile to obtain corresponding 
indole derivatives 8a - 8c.[28] Finally, indolotacrines 9a and 9b were prepared using microwave-
assisted Friedländer reaction[29] of corresponding indole 8a – 8b with cyclohexanone. 
 
  
Scheme 2: Synthesis of indolotacrines 9a, 9b, 13 and indole 8c. Reagents and conditions: a) Fe, NH4Cl, 
MeOH/H2O (3:1), 50˚C, 2h, 79%; b) trifluoroacetic anhydride, Et3N, THF, -7˚C – rt, overnight, 97-99%; 
c) malononitrile, L-proline, K2CO3, CuI, DMSO/H2O (1:1), 60˚C, overnight, 48-90%; d) cyclohexanone, 
AlCl3, 1,2-dichloroethane, microwave irradiation, 95˚C, 2h, 16-54%; e) benzaldehyde, MeOH, rt, 
overnight, 97%; f) NaBH3CN, AcOH/MeOH, 0˚C – rt, overnight, 75%; g) malononitrile, picolinic acid, 
K2CO3, CuI, DMSO, microwave irradiation, 90˚C, 12h, 26%. 
 
Indolotacrine 13 was prepared by a slightly different synthetic procedure in four steps (Scheme 2). 
Firstly, 2-iodoaniline 6 was treated with benzaldehyde to give imine 10, which was then reduced to 
corresponding amine 11 using NaBH3CN. In next step cyclization of amine 11 with malononitrile gave 
indole 12.[30] In final step the Friedländer reaction[29] of 12 with cyklohexanone gave indolotacrine 13. 
For the biological evaluation, all final products (Figure 3) were transformed into better water-soluble 
hydrochlorides by stirring them in diethyl ether saturated with HCl (g). 
  
 Figure 3: a) Indole and b) indolotacrine analogues prepared in this study. 
 
 
Both series were assayed in vitro for their inhibitory activity against membrane-bound MAO A and 
MAO B (Table 3). All the indoles were potent and unselective MAOIs, with 4c being the best inhibitor 
of both isoenzymes in the series. Indoles 4a-c were evaluated for irreversible inhibition and, 
unexpectedly, none of compounds showed significantly lower IC50 value after 30 min pre-incubation 
with enzyme, despite compounds 4b,c have the N-propargylamine moiety, which is present in many 
known irreversible MAOIs (e.g. deprenyl, clorgyline or rasagiline). This could be due to the change in 
the electron density on the triple bond of the N-propargyl motif, as its connecting nitrogen atom is 
here part of the aromatic system, in contrast to the known irreversible inhibitors where the N-
propargylamine moiety is separated from the aromatic system usually by an alkyl linker. 
Alternatively, steric hindrance from the carbonitrile substituent could prevent the generation of the 
reactive intermediate or its modification of the enzyme. Based on this finding, we decided to 
investigate whether the N-allyl or N-propargyl substitution is necessary for MAO inhibition and so we 
synthesized compound 8c. Evaluation revealed that indole 8c devoid of any N-alkyl substitution on 
the amino group at position 2 retained the inhibitory activity at level similar to other indoles, 
showing that the propargyl moiety does not contribute to the binding. 
Indolotacrine 9b retained the inhibitory activity for both MAO isoenzymes, however, 9a inhibited 
only MAO A and 13 with an extra N-benzyl substitution showed no inhibition of either MAO 
isoenzyme. It could be assumed that the extended spatial size of 13 would prevent entry into the 
active site of MAO enzymes.[31] In addition, compound 9a was tested for inactivation of MAO A but it 
showed the expected reversible mode of inhibition. Unlike the unselective indole analogues, 
indolotacrines 9a,b both exerted some selectivity towards MAO A inhibition with 9b being the most 
potent MAO A inhibitor among all the compounds tested (IC50 = 0.49 µM). Standards tacrine and 7-
MEOTA showed only moderate activity being poorer inhibitors of both MAO isoenzymes than the 
indolotacrine 9b. 
  
 Table 3: Inhibition of MAO A and MAO B. 
Compound 
MAO A 
IC50 ± SD (µM) 
MAO B 
IC50 ± SD (µM) 
SI[b] 
MAO A 30’[c] 
IC50 ± SE (µM) 
MAO B 30’[c] 
IC50 ± SE (µM) 
4a 2.32 ± 0.26 2.02 ± 0.56 0.9 1.78 ± 0.33 10.86 ± 0.78 
4b 1.32 ± 0.12 1.70 ± 0.40 1.3 1.80 ± 0.56 2.48 ± 0.32 
4c 0.68 ± 0.08 1.62 ± 0.35 2.4 0.45 ± 0.03 0.87 ± 0.10 
8c 2.80 ± 0.40 3.89 ± 0.02 1.4 - - 
9a 11.40 ± 1.10 > 100 8.8 30.0 ± 1.9 - 
9b 0.49 ± 0.05 53.90 ± 10.70 110.0 - - 
13 > 100 > 100 - - - 
tacrine 14.07 ± 1.47 317.2 ± 201.0 22.5 - - 
7-MEOTA 7.10 ± 0.03 98.61 ± 14.63 13.9 - - 
[a] IC50 and SD/SE values were obtained as a mean of 2 independent measurements 
[b] selectivity index = IC50 MAO B / IC50 MAO A 
[c] IC50 values after 30 min pre-incubation of enzyme with inhibitor 
  
All final compounds with the exception of 4c (which was a by-product of synthesis and, due to low 
yield, was tested only for MAO inhibition) and 8c (prepared subsequently to enhance SAR on MAO 
inhibition and antioxidant activity) were assayed in vitro for their inhibitory activity against human 
recombinant acetylcholinesterase (AChE) and human plasma butyrylcholinesterase (BChE) (Table 4). 
No significant inhibitory activity against AChE or BChE was detected for indoles 4a,b. Both 
compounds exerted only poor inhibition of AChE in high micromolar range and were found to be 
inactive against BChE at the highest concentration tested (50 µM). A possible explanation for this 
observation is that compounds 4a,b lack the structural complexity of other indoles or indanes, which 
are capable of ChE inhibition (e.g., the extra N-benzylpiperidine moiety present in donepezil, ASS234 
and MBA236 or the carbamate moiety of ladostigil).[22] Conversely, indolotacrines 9a,b were found to 
be potent unselective inhibitors of both ChE enzymes with IC50 values in low micromolar range, and 
compound 13 was a selective BChEI. None of the compounds were better than tacrine, but 
compound 9b was a better inhibitor of both ChEs compared to 7-MEOTA. IC50 values obtained for 




Table 4: Inhibition of AChE and BChE. 
Compound 
AChE 
IC50 ± SEM (µM) 
BChE 
IC50 ± SEM (µM) 
SI[b] 
4a 319.2 ± 15.9 > 1000 3.1 
4b 101.9 ± 5.4 > 1000 9.8 
9a 11.6 ± 0.6 4.7 ± 0.1 0.4 
9b 1.5 ± 0.1 2.4 ± 0.1 1.6 
13 > 1000 1.09 ± 0.07 0.001 
tacrine 0.32 ± 0.01 0.088 ± 0.001 0.3 
7-MEOTA 10.0 ± 1.0 17.6 ± 0.8 1.8 
[a] IC50 and SEM values were obtained as a mean of 3 independent measurements 
[b] selectivity index = IC50 BChE / IC50 AChE 
 
Additionally, as ROS are likely to play a part in the development and progression of AD,[33] the 
compounds were evaluated for their antioxidant activity using DPPH assay (Table 5). Indoles 4a,b 
showed promising antioxidant properties, similar to the standard N-acetylcysteine and only slightly 
weaker than trolox. We hypothesized that this could be due to the presence of phenolic group, which 
is a key structural motif common of many antioxidants.[34] To prove this assumption we synthesized 
compound 8c, where the phenolic group was replaced with chlorine. Evaluation showed, in good 
correlation with our hypothesis, that indole 8c exerts more than 20 times weaker antioxidant activity 
compared to phenolic compounds 4a and 4b. Neither the indolotacrines nor tacrine or 7-MEOTA 
showed any significant antioxidant activity, which is not surprising, as they all lack the phenolic group 
responsible for this activity as demonstrated for the indoles. Introduction of the phenolic moiety 
therefore presents a possible improvement of the indolotacrine compounds for the future. 
Table 5: Antioxidant activity and cytotoxicity of prepared compounds. 
Compound 
Antioxidant activity 
EC50 ± SEM (µM) 
Cytotoxicity 
IC50 ± SEM (µM) 
4a 37.86 ± 5.01 > 1000 
4b 25.82 ± 1.35 > 1000 
8c 731.70 ± 27.17 113 ± 29 
9a ˃ 5000 13.0 ± 1.4 
9b ˃ 5000 5.5 ± 0.4 
13 3827.0 ± 227.1 7.0 ± 0.7 
tacrine ˃ 5000 248 ± 11 
7-MEOTA ˃ 5000 63 ± 4 
 N-acetylcystein 27.91 ± 1.82 - 
trolox 16.20 ± 0.42 - 
[a] EC50/IC50 and SEM values were obtained as a mean of 3 independent measurements 
 
Next, the cytotoxicity of the compounds was evaluated using the MTT assay on the CHO-K1 cell line 
(Table 5). Indoles were found to possess very low toxicity with IC50 values above the measurable 
range (>1000 µM) in case of 4a,b and at high microlomolar range for 8c. All indolotacrines exerted 
similar level of cytotoxicity with IC50 values around 10 µM. Standards 7-MEOTA and tacrine were both 
found to be less toxic, with tacrine being the least toxic compound among the series in vitro. This 
could be considered quite a surprising result as it is known that in vivo tacrine is more toxic than 7-
MEOTA.[35] 
Assuming that the principal target of tacrine toxicity in vivo is liver, we decided to evaluate tacrine 
and 7-MEOTA together with the most promising indolotacrine 9b for their hepatotoxicity on the 
HepG2 cell line using the MTT assay (Table 6).[36] Compound 9b was found to be more hepatotoxic 
compared to 7-MEOTA and tacrine. As in cytotoxicity evaluation, tacrine showed lower in vitro 
hepatotoxicity compared to 7-MEOTA, which is at odds with the in vivo results.[35] A possible 
explanation for this peculiarity is that the hepatoxicity is not caused by tacrine itself but by its 
metabolites, products of cytochrome P450 oxidation.[37] Therefore it is hard to conclude about the 
compounds’ toxicity in vivo (e.g. 9b) based on the results of in vitro testing and these cytotoxicity and 
hepatotoxicity assessments have, in this case, only generally informative character. 
Table 6: Hepatotoxicity evaluation. 
Compound 
Hepatotoxicity 
IC50 ± SEM (µM) 
9b 1.22 ± 0.11 
tacrine 17.28 ± 0.76 
7-MEOTA 11.50 ± 0.77 
[a] IC50 and SEM values were obtained as a mean of 3 independent measurements 
 
Penetration across the blood-brain barrier (BBB) is an essential property for compounds targeting the 
CNS and should always be considered during the drug development. In order to predict passive BBB 
penetration, modification of the parallel artificial membrane permeation assay (PAMPA) has been 
used based on reported protocol.[38] As summarized in Table 7, it is obvious that compound 9b has a 
high potential to be available in the CNS. Data obtained for the new compound were correlated to 
standard drugs, where CNS availability is known and also reported using the PAMPA assay.[38] Our 
data show high resemblance with previously reported penetrations as well as with a general 
knowledge about the availability in the CNS of such standard drugs. 
  
  
Table 7: Prediction of blood-brain barrier penetration of 9b and reference compounds. 
Compound 
BBB penetration estimation 
Pe ± SEM (10
-6 cm s-1) CNS (+/-)[b] 
9b 6.6 ± 0.65 (+) 
donepezil 7.3 ± 0.9 (+) 
rivastigmine 6.6 ± 0.5 (+) 
tacrine 5.3 ± 0.19 (+) 
testosterone 11.3 ± 1.6 (+) 
chlorpromazine 5.6 ± 0.6 (+) 
hydrocortisone 2.85 ± 0.1 (+/-) 
piroxicam 2.2 ± 0.15 (+/-) 
theophyline 1.07 ± 0.18 (-) 
atenolol 1.02 ± 0.37 (-) 
[a] Pe and SEM values were obtained as a mean of 4 independent measurements          
[b]   (+) (high BBB permeation predicted) Pe (10
-6 cm s-1) > 4.0 
  (-) (low BBB permeation predicted) Pe (10
-6 cm s-1) < 2.0 
  (+/-) (BBB permeation uncertain) Pe (10
-6 cm s-1) = 2.0 – 4.0 
 
In summary, in this work we have reported design, synthesis and in vitro evaluation of series of 
indoles and series of indolotacrine hybrid analogues as potential drugs for the treatment of AD. The 
novel compounds were designed as MTDLs targeting primarily ChEs and MAOs. In addition to ChE 
and MAO inhibition, the biological evaluation also involved determination of antioxidant, cytotoxic 
and hepatotoxic properties and permeability prediction (BBB assay). The most promising compound, 
indolotacrine 9b, was found to be a potent inhibitor of AChE (IC50 = 1.5 µM), BChE (IC50 = 2.4 µM) and 
MAO A (IC50 = 0.49 µM) and weak inhibitor of MAO B (IC50 = 53.9 µM). The inhibitory activity of 9b 
against ChEs and MAOs seems quite well balanced, and thus has potential for the desired 
simultaneous multi-target directed action in vivo, but the optimal balance of inhibitory ability against 
each target in AD is still not known.[39] The cytotoxic and hepatotoxic profile of 9b are slightly inferior 
to the standards, tacrine and 7-MEOTA, but the overall improvement in the enzymatic inhibitory 
activities and potential to cross BBB make indolotacrine 9b a promising lead compound for further 
development and investigation. 
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